Nasal biomarker inflammatory profile in response to intranasal corticosteroids in pediatric obstructive sleep apnea syndrome.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
STUDY OBJECTIVES: Nasopharyngeal inflammation contributes to pediatric obstructive sleep apnea syndrome (OSAS). Intranasal corticosteroids (INCS) are used to treat pediatric OSAS; a randomized controlled trial showed an improvement in OSAS symptoms but without polysomnography or neurobehavioral outcome differences. There is a lack of data demonstrating an objective decrease in the nasal inflammatory biomarker profile associated with INCS. Hence, we evaluated the association of nasal inflammatory biomarker profile and response to INCS. METHODS: Secondary analysis of a randomized controlled trial of INCS vs placebo in pediatric OSAS (n = 134). The difference in intranasal biomarkers (interleukin (IL)-4, IL-13, tumor necrosis factor-alpha) between the groups after 3 and 12 months was evaluated. The association of the nasal inflammatory biomarker profile and response to INCS was assessed. Multiple regression analysis was performed to identify clinical predictors of response to INCS. RESULTS: There were no statistically significant differences in the nasal IL-4, IL-13, and tumor necrosis factor-alpha levels between INCS and placebo groups after 3 and 12 months of treatment. Within the INCS group, there was no statistically significant change in the nasal IL-4, IL-13, and tumor necrosis factor-alpha levels after 3 months of therapy based on responder status. However, among those who received INCS, obesity and a higher obstructive apnea-hypopnea index at baseline were clinical predictors of greater obstructive apnea-hypopnea index after 3 months (P = .038 and .002, respectively). CONCLUSIONS: INCS did not affect the nasal inflammatory biomarker profile in children with OSAS, including the responders. In addition, INCS is not recommended as a treatment option in children with obesity or high obstructive apnea-hypopnea index at baseline. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Steroids for Pediatric Apnea Research in Kids (SPARK); URL: https://clinicaltrials.gov/study/NCT02180672; Identifier: NCT02180672. CITATION: Chidambaram AG, Cielo CM, Chervoneva I, Spergel JM, Tapia IE. Nasal biomarker inflammatory profile in response to intranasal corticosteroids in pediatric obstructive sleep apnea syndrome. J Clin Sleep Med. 2025;21(6):1033-1040.